Literature DB >> 26108652

Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.

Pathik Parikh1, Jatin Patel, Meghraj Ingle, Prabha Sawant.   

Abstract

AIM: The aims of the study were to determine the levels of serum ferritin which predict fibrosis in Indian patients with nonalcoholic fatty liver disease (NAFLD) and to establish correlation between Fibroscan values and serum ferritin levels.
METHODS: The clinical, biochemical, radiologic, and histological findings of consecutive adult NAFLD patients accessed at a tertiary care center over a 3-year period were analyzed. Those with concurrent liver diseases were excluded. Fifty-five of 250 NAFLD patients with fatty liver on ultrasound and raised enzymes (>40 IU/L) underwent liver biopsy. Patients were stratified into two groups based on their histological stage steatosis (with or without inflammation) but no fibrosis and nonalcoholic steatohepatitis (NASH) with fibrosis/cirrhosis. Serum ferritin levels were measured at the same time as getting liver biopsy. Fibroscan was carried out in each of these patients. These were compared with 50 age- and sex-matched controls with normal ultrasound, liver enzymes, and no history of alcohol. Student's t test was used as the test for significance.
RESULTS: Fifty-five NAFLD patients diagnosed on ultrasound and with raised enzymes underwent biopsy. Steatosis (with or without inflammation, but no fibrosis/ballooning) was seen in 35 patients, fibrosis/ballooning in 14 patients, and cirrhosis in 6 patients. Mean ferritin levels in groups with nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) were 39.4 and 72.7 ng/mL, respectively (p < 0.001). The mean ferritin levels in NAFLD and controls were 51.2 and 35.2 ng/mL, respectively (p < 0.05). The area under the curve (AUC) of serum ferritin at value 48.0 ng/mL was 0.779. The coefficient of correlation between Fibroscan and serum ferritin levels was 0.9864 while that with alanine transaminase and aspartate aminotransferase was 0.69. Serum ferritin at the cutoff of 48 ng/mL differentiated significantly patients with fibrosis and higher Fibroscan levels.
CONCLUSION: Serum ferritin was low in Indian individuals, and levels even within apparently normal range indicated fibrosis and cirrhosis. A cutoff level of 48.0 IU/mL distinguished fibrosis in NAFLD. Fibroscan correlated well with serum ferritin levels.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26108652     DOI: 10.1007/s12664-015-0572-5

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  29 in total

1.  Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Kris V Kowdley; Patricia Belt; Laura A Wilson; Matthew M Yeh; Brent A Neuschwander-Tetri; Naga Chalasani; Arun J Sanyal; James E Nelson
Journal:  Hepatology       Date:  2011-12-06       Impact factor: 17.425

Review 2.  Ferritin regulation by oxidants and chemopreventive xenobiotics.

Authors:  John Wilkinson; E Christine Pietsch; Suzy V Torti; Frank M Torti
Journal:  Adv Enzyme Regul       Date:  2003

3.  Ferritin and the response to oxidative stress.

Authors:  K Orino; L Lehman; Y Tsuji; H Ayaki; S V Torti; F M Torti
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

4.  Induction of ferritin synthesis by oxidative stress. Transcriptional and post-transcriptional regulation by expansion of the "free" iron pool.

Authors:  G Cairo; L Tacchini; G Pogliaghi; E Anzon; A Tomasi; A Bernelli-Zazzera
Journal:  J Biol Chem       Date:  1995-01-13       Impact factor: 5.157

5.  Effects of TNF-alpha and IL-1beta on iron metabolism by A549 cells and influence on cytotoxicity.

Authors:  I M Smirnov; K Bailey; C H Flowers; N W Garrigues; L J Wesselius
Journal:  Am J Physiol       Date:  1999-08

6.  Interleukin 1 induces ferritin heavy chain in human muscle cells.

Authors:  Y Wei; S C Miller; Y Tsuji; S V Torti; F M Torti
Journal:  Biochem Biophys Res Commun       Date:  1990-05-31       Impact factor: 3.575

7.  Serum ferritin is associated with non-alcoholic fatty liver disease and decreased Β-cell function in non-diabetic men and women.

Authors:  Kristina M Utzschneider; Anna Largajolli; Alessandra Bertoldo; Santica Marcovina; James E Nelson; Matthew M Yeh; Kris V Kowdley; Steven E Kahn
Journal:  J Diabetes Complications       Date:  2013-11-26       Impact factor: 2.852

8.  The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West.

Authors:  Ajay Duseja; Ashim Das; Reena Das; R K Dhiman; Y Chawla; A Bhansali; Naveen Kalra
Journal:  Dig Dis Sci       Date:  2007-04-10       Impact factor: 3.199

9.  Ferritin--a mediator of apoptosis?

Authors:  Nikolaus Bresgen; Ingo Ohlenschläger; Brigitte Fiedler; Nathalie Wacht; Susanne Zach; Bettina Dunkelmann; Paolo Arosio; Elisabeth Kuffner; Friedrich Lottspeich; Peter M Eckl
Journal:  J Cell Physiol       Date:  2007-07       Impact factor: 6.384

10.  Body iron, serum ferritin, and nonalcoholic fatty liver disease.

Authors:  Jae-Jun Shim
Journal:  Korean J Hepatol       Date:  2012-03-22
View more
  4 in total

1.  Cutoff Values for Serum Ferritin in Predicting Cirrhosis Severity due to Cholestatic Jaundice in Vietnamese Children.

Authors:  Ha-Van Thieu; Thach Binh Minh; Tran-Thi Khanh Tuong; Nguyen Minh Duc
Journal:  Med Arch       Date:  2022-04

2.  Association between serum ferritin level and the various stages of non-alcoholic fatty liver disease: A systematic review.

Authors:  Huanqiu Wang; Ruyu Sun; Sisi Yang; Xueqing Ma; Chengbo Yu
Journal:  Front Med (Lausanne)       Date:  2022-08-03

3.  C-peptide as a key risk factor for non-alcoholic fatty liver disease in the United States population.

Authors:  Amporn Atsawarungruangkit; Jirat Chenbhanich; George Dickstein
Journal:  World J Gastroenterol       Date:  2018-08-28       Impact factor: 5.742

4.  Serum ferritin as a non-invasive marker in the prediction of hepatic fibrosis among Egyptian patients with non-alcoholic fatty liver disease.

Authors:  Noha El Nakeeb; Shereen A Saleh; Yasmine M Massoud; Ahmed Hussein; Rana Hamed
Journal:  JGH Open       Date:  2017-11-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.